Alvotech Shares Surge After Barclays Upgrade Cites Favorable FDA Inspection

Shares of Alvotech (ALVO) rallied 5.6% in pre-market trading after Barclays upgraded the biotechnology firm to Overweight from Underweight, doubling its price target to $8.00 from $4.00. The analyst action was driven by a significantly improved regulatory outlook following a key U.S. Food and Drug Administration (FDA) inspection decision.

Regulatory Hurdles Cleared

The upgrade hinges on the FDA's recent classification of its May 2026 inspection of Alvotech’s Reykjavik, Iceland, manufacturing plant. The agency closed the inspection with a Voluntary Action Indicated (VAI) notice, which is its most favorable outcome and removes a significant regulatory uncertainty that had weighed on the stock, according to Barclays.

This positive development allowed Alvotech to resubmit Biologics License Applications (BLAs) in June for several key products. Investors are now focused on a series of upcoming regulatory milestones:

• December 4, 2026: The FDA's target review completion date for biosimilars to Johnson & Johnson's Simponi, Regeneron's Eylea, and Amgen's Prolia/Xgeva.
• Early 2027: An anticipated decision on AVT16, a proposed biosimilar to Takeda's Entyvio, for which the FDA has accepted a BLA.

Ad

Analyst Reversal and Market Impact

Barclays' new position marks a notable reversal for analyst Glen Santangelo, who had previously expressed concerns about Alvotech's leverage and capital expenditure needs. The upgrade signals renewed confidence that the path to commercialization for its pipeline is now clearer.

While the broader U.S. equity market showed modest gains in early trading, Alvotech's sharp upward move was distinctly company-specific. The combination of a high-conviction analyst upgrade and concrete regulatory progress has provided a powerful catalyst for the shares. Despite the rally, the stock remains below its 52-week high of $9.25, suggesting potential for further gains if the company secures the anticipated FDA approvals on schedule.